Slovakia Approves Sputnik V Vaccine
RDIF has announced that the Sputnik V vaccine for COVID-19 has been approved in Slovakia under the emergency use authorization procedure.
In a March 1, 2021 press release, the Russian Direct Investment Fund (RDIF) announced that the Sputnik V vaccine for COVID-19 has been approved in Slovakia under the emergency use authorization procedure.
The latest approval marks the second within the European Union for the Russian vaccine and makes Slovakia the 39th country in the world to authorize the use of Sputnik V in coronavirus patients. The Slovakian authorization decision was based on a comprehensive assessment of the vaccine by Slovakian experts and the results of the Russian clinical trials.
“In Europe Sputnik V vaccine has been approved in Slovakia, Hungary, San-Marino, Serbia, Montenegro, Republika Srpska, Belarus, and Russia with other countries of the region also showing strong interest in it,” saidKirill Dmitriev, CEO of RDIF, in the press release. “Vaccine partnership and diversification of national vaccine portfolios are the key for helping people feel safe and protected, restoring economic activity, and ending the pandemic as soon as possible. We have received numerous requests from EU states to provide Sputnik V directly to them based on the reviews of their national agencies. We will continue to do so as well as work with [the European Medicines Agency] based on the rolling review procedure we initiated in January.”
Source: RDIF
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
